Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04360252 · ClinicalTrials.gov registry record · NA
Gracie Diet for Gastroesophageal Reflux Disease
A NA study of Gastroesophageal Reflux and GERD, sponsored by Johns Hopkins University.
- Active
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT04360252: Active NA study of Gastroesophageal Reflux and GERD, sponsored by Johns Hopkins University.
NCT04360252 is a NA study of Gastroesophageal Reflux and GERD that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 30 participants, below the 2,885-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04360252, a NA study of Gastroesophageal Reflux and GERD, is active but no longer recruiting, sponsored by Johns Hopkins University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if dietary changes can help improve gastroesophageal reflux disease (GERD) symptoms. The main question\[s\] it aims to answer whether the Gracie Diet is an option to treat GERD symptoms in individuals wish to discontinue standard doses of PPI and / or H2 receptor antagonists. Participants will be taken off PPI and be placed on the Gracie Diet for 8 weeks. Information about the participants reflux symptoms and GERD health related quality of life will be collected to assess the effect of the diet.
Primary Outcome
The effect of the Gracie Diet in GERD symptoms by changes in the UCLA SCTC GIT 2.0 score. The UCLA-SCTC GIT 2.0 is a multi-item instrument that measures GI symptoms and the impact on health related quality of life. Includes 34 questions in 7 domains (reflux, distension, soilage, diarrhea, social function, emotional wellbeing and constipation) during a 7 day recall period. Each domain is weighted and scored, and a total score is then calculated.
Conditions Studied
Interventions
- OTHER Gracie Diet
Study Locations (1)
Maryland
- Johns Hopkins Bayview Medical Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-11-13 |
| Est. Completion | 2027-12 |
| Phase | NA |
What the registry record for NCT04360252 still lists
NCT04360252 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,885-participant average among 33 other Gastroesophageal Reflux trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Gastroesophageal Reflux appearing as the primary indexed condition, and to 1 intervention - of which Gracie Diet is the first listed.
NCT04360252 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04360252 about?
NCT04360252 is a clinical study titled "Gracie Diet for Gastroesophageal Reflux Disease". The goal of this clinical trial is to learn if dietary changes can help improve gastroesophageal reflux disease (GERD) symptoms. The main question\[s\] it aims to answer whether the Gracie Diet is an option to treat GERD symptoms in individuals wish to discontinue standard doses of PPI and / or H2 r...
What is the current status of trial NCT04360252?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2020-11-13. Estimated completion is 2027-12.
What conditions does trial NCT04360252 study?
This clinical trial studies the following conditions: Gastroesophageal Reflux, GERD.
What interventions are being tested in trial NCT04360252?
The interventions under investigation include: Gracie Diet (OTHER).
Who is sponsoring clinical trial NCT04360252?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04360252 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroesophageal Reflux
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04360252's enrollment target sits among peer trials
30 31st of 33 higher than 2 of 33 other Gastroesophageal Reflux trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastroesophageal Reflux trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Breath Testing for Small Intestinal Bacterial Overgrowth
RECRUITING · NA
-
Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia
RECRUITING · NA
-
Compassionate Use of Domperidone for Refractory Gastroparesis
RECRUITING · NA
-
External UES Band (Shaker Pressure Band) and GERD
RECRUITING · NA
-
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
RECRUITING · NA
-
Establishing Pressures at the EGJ During Diaphragmatic Breathing Using High-resolution Esophageal Manometry
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI